Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 5, 2026

Samsara projects FY 2027 revenue of $2.005B-$2.013B while targeting 20% non-GAAP operating margin

View original at seekingalpha.com
Samsara projects FY 2027 revenue of $2.005B-$2.013B while targeting 20% non-GAAP operating margin Earnings Call Insights: Samsara (IOT) Q1 fiscal 2027 MANAGEMENT VIEW * "Samsara delivered a strong start to FY '27, with another quarter of durable and efficient growth" (CEO Sanjit Biswas), including: "We ended Q1 with ne…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Samsara uses coding bots and agents internally and is automating workflows

    60% confidence
  • Emerging products were more than 20% of net new ACV in Q1 versus 23% of net new ACV in Q4 FY2026

    60% confidence
  • Samsara is experimenting with different pricing models for new intelligence products

    60% confidence
  • In Q1, Samsara added 169 customers with $100,000+ ARR and 15 customers with $1 million+ ARR

    60% confidence
  • The Hertz deal covers approximately 0.5 million vehicles

    60% confidence
  • Large customers see an opportunity to bring workflows together on one platform

    60% confidence
  • For full year FY '27, Samsara expects revenue between $2.005 billion and $2.013 billion

    60% confidence
  • Customer expansions are more driven by more assets or licenses on the same product

    60% confidence
  • AI/cloud cost pressure is being mitigated via COGS-related optimizations and OPEX reallocation

    60% confidence
  • Samsara ended Q1 with nearly $2 billion in ARR, growing 30% year-over-year

    60% confidence
  • Q1 revenue was $479 million

    60% confidence
  • Waste Intelligence is monetized as additional SKUs

    60% confidence
  • Non-GTM functions may be roughly the same size, if not smaller

    60% confidence
  • There is no unusual seasonality behind the modest-looking Q2 guidance step despite the raised full-year guide

    60% confidence
  • Samsara delivered a strong start to FY '27, with another quarter of durable and efficient growth

    60% confidence
  • The full-year guide raise is almost double the amount of the Q1 beat

    60% confidence
  • Samsara is emphasizing LTM (last 12 months) figures to reduce perceived volatility from large deal timing

    60% confidence
  • Memory market visibility isn't as good as it has been in the past

    60% confidence
  • GAAP EPS would still be positive excluding the Motive arbitration award

    60% confidence
  • $100,000-plus customers represent 62% of total ARR

    60% confidence
  • Free cash flow margin was 15%

    60% confidence
  • Samsara hasn't had a problem stocking component supply despite tighter memory markets

    60% confidence
  • DRAM and NAND supply chain conditions are a little bit tighter

    60% confidence
  • Samsara is expanding into maintenance, training, qualifications, and workflows

    60% confidence
  • GAAP EPS was a positive $0.08

    60% confidence
  • Q2 non-GAAP EPS expected to be between $0.15 and $0.16

    60% confidence
  • In May, Samsara gathered hundreds of public sector customers at Go Beyond event in Chicago, introducing Waste Intelligence, Ground Intelligence, and Ridership Management

    60% confidence
  • Samsara expects to be GAAP profitable for Q2

    60% confidence
  • At some point Samsara may offer a consumption-based pricing model for agents

    60% confidence
  • Samsara signed 11 $1 million-plus net new ACV transactions in Q1

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com